• 1
    Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 315.
  • 2
    Horowitz L, Farrar JT. Intraluminal small intestinal pressure in normal patients and in patients with functional gastrointestinal disorders. Gastroenterology 1962; 42: 45564.
  • 3
    Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92: 188593.
  • 4
    Small PK, Loudon MA, Hau CM, Noor N, Campbell FC. Large-scale ambulatory study of postprandial jejunal motility in irritable bowel syndrome. Scand J Gastroenterol 1997; 32: 3947.
  • 5
    Chaudhary NA, Truelove SC. Human colonic motility: a comparative study of normal subjects, patients with ulcerative colitis, and patients with the irritable colon syndrome. (I) Resting patterns of colonic motility. Gastroenterology 1961; 40: 117.
  • 6
    Connell AM. The motility of the pelvic colon. (II) Paradoxical motility in diarrhoea and constipation. Gut 1962; 3: 3428.
  • 7
    Bazzocchi G, Ellis J, Villanueva-Meyer J, Reddy SN, Mena I, Snape WJ. Effect of eating on colonic motility and transit in patients with functional diarrhoea. Simultaneous scintigraphic and manometric evaluations. Gastroenterology 1991; 101: 1298306.
  • 8
    Vasallo MJ, Camilleri M, Phillips SF, et al.Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc 1992; 67: 72531.
  • 9
    Bassotti G, Gaburri M, Imbimbo BP, et al.Colonic mass movements in idiopathic chronic constipation. Gut 1988; 29: 11739.
  • 10
    Choi MG, Camilleri M, O'Brien MD, Kammer PP, Hanson RB. A pilot study of motility and tone of the left colon in patients with diarrhoea due to functional disorders and dysautonomia. Am J Gastroenterol 1997; 92: 297302.
  • 11
    Prior A, Maxton DG, Whorwell PJ. Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 1990; 31: 45862.
  • 12
    Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Evaluation of colonic sensory thresholds in IBS patients using a barostat. Dig Dis Sci 1994; 39: 44957.
  • 13
    Mertz H, Naliboff B, Manukata J, Niazi N, Mayer EA. Altered bowel rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 4052.
  • 14
    Munakata J, Naliboff B, Farzaneh H, et al.Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112: 5563.
  • 15
    Naliboff BD, Munakata J, Fullerton S, et al.Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997; 41: 50512.
  • 16
    Basotti G, Gaburri M, Imbimbo BP, Morelli A, Whitehead WE. Distension-stimulated propagated contractions in human colon. Dig Dis Sci 1994; 39: 195560.
  • 17
    Briejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 63151.
  • 18
    Bearcroft CP, Perrett D, Farthing MJG. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998; 42: 426.
  • 19
    Humphrey PPA, Bountra C, Clayton NM, Kozlowski CM. The therapeutic potential of 5-HT3 antagonist in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 318.
  • 20
    Bardhan KD, Bodemar G, Geldof H, et al.A double-blind, randomized, placebo-controlled dose ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 2334.
  • 21
    Camilleri M, Mayer EA, Drossman DA, et al.Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 114959.DOI: 10.1046/j.1365-2036.1999.00610.x
  • 22
    Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 103540.
  • 23
    Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 84955.DOI: 10.1046/j.1365-2036.1998.00375.x
  • 24
    Houghton LA, Forster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 77582.DOI: 10.1046/j.1365-2036.2000.00762.x
  • 25
    Samsom M, Smout AJ, Hebbard G, et al.A novel portable perfused manometric system for recording of small intestinal motility. Neurogastroenterol Motil 1998; 10: 13948.
  • 26
    Bassotti G, Gaburri M. Manometric investigation of high-amplitude propagated contractile activity of the human colon. Am J Physiol 1988; 255: G6604.
  • 27
    Degen LP, Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut 1996; 39: 299305.
  • 28
    Vassallo M, Camilleri M, Phillips SF, et al.Transit through the proximal colon influences stool weight in irritable bowel syndrome. Gastroenterology 1992; 102: 1028.
  • 29
    Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol 1994; 19: 2830.
  • 30
    Bazzocchi G, Ellis J, Villanueva-Meyer J, et al.Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology 1990; 98: 68693.
  • 31
    Cook IJ, Furukawa Y, Panagopoulos V, Collins PJ, Dent J. Relationships between spatial patterns of colonic pressure and individual movements of content. Am J Physiol Gastrointest Liver Physiol 2000; 278: G32941.
  • 32
    Von der Ohe MR, Hanson RB, Camilleri M. Serotinergic mediation of postprandial colonic tonic and phasic responses in humans. Gut 1994; 35: 53641.
  • 33
    Sanger GJ. 5-Hydroxytryptamine and functional bowel disorders. Neurogastroenterol Motil 1996; 8: 31931.
  • 34
    Saslow SB, Scolapio JS, Camilleri M, et al.Medium term effects of a new 5-HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Gut 1998; 42: 62834.
  • 35
    Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 86978.DOI: 10.1046/j.1365-2036.2000.00786.x
  • 36
    Kozlowski CM, Green A, Grundy D, Boissonade FM, Bountra C. The 5-HT3 antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46: 47480.DOI: 10.1136/gut.46.4.474